Balversa, Janssen
Erdafitinib Shows Promise in Advanced Bladder Cancer
The fibroblast growth factor receptor inhibitor erdafitinib (Balversa, Janssen) showed promising antitumor activity ...
AUGUST 23, 2019
FDA Approves First FGFR Kinase Inhibitor for Advanced Bladder Ca
The FDA granted accelerated approval to erdafitinib (Balversa, Janssen) for the treatment of adults with locally ...
APRIL 17, 2019
Load more